130 related articles for article (PubMed ID: 38127437)
1. Clinical efficacy and safety of canagliflozin combined with valsartan in the treatment of early and mid-stage diabetic nephropathy.
Ma D; Cao T
Minerva Surg; 2024 Jun; 79(3):368-370. PubMed ID: 38127437
[No Abstract] [Full Text] [Related]
2. Will Canagliflozin Lend Credence to the Potential Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Renal Endpoints in Diabetic Nephropathy.
Neumiller JJ; Rhee CM; Kalantar-Zadeh K
Am J Nephrol; 2017; 46(6):459-461. PubMed ID: 29227973
[No Abstract] [Full Text] [Related]
3. Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial.
Wada T; Mori-Anai K; Kawaguchi Y; Katsumata H; Tsuda H; Iida M; Arakawa K; Jardine MJ
J Diabetes Investig; 2022 Jan; 13(1):54-64. PubMed ID: 34212533
[TBL] [Abstract][Full Text] [Related]
4. Two cases of advanced stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor.
Morino J; Hirai K; Kaneko S; Minato S; Yanai K; Mutsuyoshi Y; Ishii H; Matsuyama M; Kitano T; Shindo M; Aomatsu A; Miyazawa H; Ito K; Ueda Y; Hoshino T; Ookawara S; Hara K; Morishita Y
CEN Case Rep; 2019 May; 8(2):128-133. PubMed ID: 30663011
[TBL] [Abstract][Full Text] [Related]
5. CREDENCE: A silver lining in the dark cloud of diabetic nephropathy.
Hanai K; Babazono T
J Diabetes Investig; 2020 May; 11(3):527-529. PubMed ID: 31705732
[No Abstract] [Full Text] [Related]
6. [In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?].
Lanthier L; Huard G; Plourde MÉ; Cauchon M
Rev Med Interne; 2020 Jan; 41(1):67-68. PubMed ID: 31812446
[No Abstract] [Full Text] [Related]
7. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m
Bakris G; Oshima M; Mahaffey KW; Agarwal R; Cannon CP; Capuano G; Charytan DM; de Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Neal B; Oh R; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Jardine MJ; Perkovic V
Clin J Am Soc Nephrol; 2020 Dec; 15(12):1705-1714. PubMed ID: 33214158
[TBL] [Abstract][Full Text] [Related]
8. How Does CREDENCE Inform Best Use of SGLT2 Inhibitors in CKD?
Neumiller JJ; Kalyani RR
Clin J Am Soc Nephrol; 2019 Nov; 14(11):1667-1669. PubMed ID: 31575617
[No Abstract] [Full Text] [Related]
9. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
Jardine MJ; Zhou Z; Mahaffey KW; Oshima M; Agarwal R; Bakris G; Bajaj HS; Bull S; Cannon CP; Charytan DM; de Zeeuw D; Di Tanna GL; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Qiu R; Sun T; Wheeler DC; Zhang H; Zinman B; Rosenthal N; Perkovic V;
J Am Soc Nephrol; 2020 May; 31(5):1128-1139. PubMed ID: 32354987
[TBL] [Abstract][Full Text] [Related]
10. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW;
N Engl J Med; 2019 Jun; 380(24):2295-2306. PubMed ID: 30990260
[TBL] [Abstract][Full Text] [Related]
11. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
Wanner C
Nat Rev Nephrol; 2018 Feb; 14(2):78-80. PubMed ID: 29307892
[No Abstract] [Full Text] [Related]
12. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
13. Research digest: SGLT2 inhibition in kidney and liver disease.
Preiss D; Sattar N
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):427. PubMed ID: 31103176
[No Abstract] [Full Text] [Related]
14. A
Nadkarni GN; Takale D; Neal B; Mahaffey KW; Yavin Y; Hansen MK; Fleming F; Heerspink HJL; Coca SG
Kidney360; 2022 Sep; 3(9):1599-1602. PubMed ID: 36245651
[TBL] [Abstract][Full Text] [Related]
15. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells.
Maki T; Maeno S; Maeda Y; Yamato M; Sonoda N; Ogawa Y; Wakisaka M; Inoguchi T
Sci Rep; 2019 Mar; 9(1):4703. PubMed ID: 30886225
[TBL] [Abstract][Full Text] [Related]
16. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
Zhou Z; Jardine MJ; Li Q; Neuen BL; Cannon CP; de Zeeuw D; Edwards R; Levin A; Mahaffey KW; Perkovic V; Neal B; Lindley RI;
Stroke; 2021 May; 52(5):1545-1556. PubMed ID: 33874750
[TBL] [Abstract][Full Text] [Related]
17. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
Yi TW; Smyth B; Di Tanna GL; Arnott C; Cardoza K; Kang A; Pollock C; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Heerspink HJL; Neal B; Wheeler DC; Cannon CP; Zhang H; Zinman B; Perkovic V; Levin A; Mahaffey KW; Jardine M;
Am J Kidney Dis; 2023 Jul; 82(1):84-96.e1. PubMed ID: 36889425
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose co-transporter type 2 inhibitors reduce evening home blood pressure in type 2 diabetes with nephropathy.
Takenaka T; Kishimoto M; Ohta M; Tomonaga O; Suzuki H
Diab Vasc Dis Res; 2017 May; 14(3):258-261. PubMed ID: 28467199
[TBL] [Abstract][Full Text] [Related]
19. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A
Oshima M; Neuen BL; Li J; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; De Nicola L; Pollock C; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL
J Am Soc Nephrol; 2020 Dec; 31(12):2925-2936. PubMed ID: 32998938
[TBL] [Abstract][Full Text] [Related]
20. Diabetic kidney disease in primary care.
Fong JMN; Tsang LPM; Kwek JL; Guo W
Singapore Med J; 2020 Aug; 61(8):399-405. PubMed ID: 32875340
[No Abstract] [Full Text] [Related]
[Next] [New Search]
